"Cardiovascular complications associated with novel agents in the chron" by Udhayvir Singh Grewal, Sahith Reddy Thotamgari et al.

Faculty Publications

Title

Cardiovascular complications associated with novel agents in the chronic lymphocytic leukemia armamentarium: A pharmacovigilance analysis

Authors

Udhayvir Singh Grewal, Department of Internal Medicine, Louisiana State University Health Sciences Center, Shreveport, LA, USA.
Sahith Reddy Thotamgari, Department of Internal Medicine, Louisiana State University Health Sciences Center, Shreveport, LA, USA.
Aakash Rajendra Sheth, Department of Internal Medicine, Louisiana State University Health Sciences Center, Shreveport, LA, USA.
Shiva Jashwanth Gaddam, Department of Internal Medicine, Louisiana State University Health Sciences Center, Shreveport, LA, USA.
Javaria Ahmad, Department of Internal Medicine, Louisiana State University Health Sciences Center, Shreveport, LA, USA.
Kavitha Beedupalli, Division of Hematology and Oncology, Department of Medicine, Louisiana State University Health Sciences Center, Shreveport, LA, USA.
Paari Dominic, Division of Cardiology, Department of Medicine, and Center for Cardiovascular Diseases and Sciences, Louisiana State University Health Sciences Center, Shreveport, LA, USA. Electronic address: paari.dominic@lsuhs.edu.

Document Type

Article

Publication Date

12-1-2021

Abstract

INTRODUCTION: Over the last few years, improved outcomes in patients with chronic lymphocytic leukemia (CLL) have been credited to the introduction of novel agents for its treatment. However, the overall cardiovascular safety profile of these agents has not been studied adequately. METHODS: We searched the Food and Drug Administration Adverse Event Reporting System (FAERS) database for adverse events reported for several of these novel agents: ibrutinib, acalabrutinib, venetoclax, and idelalisib. RESULTS: A total of 6074 cardiac adverse events were identified; ibrutinib (4832/36581; 13.2%) was found to have the highest risk of cardiac adverse events. The frequency of atrial fibrillation was highest (41.5%) in the ibrutinib group, while the idelalisib and acalabrutinib groups had the highest reported frequencies of heart failure (25.1%) and myocardial infarction (13.6%), respectively. Hypertension was noted to be relatively higher in the acalabrutinib (25.6%) and venetoclax (11.8%) groups. Overall reported mortality associated with cardiac events was highest in the venetoclax (29.4%) and idelalisib (27.1%) groups. CONCLUSION: Novel agents in the CLL armamentarium have been associated with several cardiovascular adverse events. Further studies are needed to identify high-risk groups that would benefit from robust cardiovascular surveillance after initiation of treatment with these novel agents.

Publication Source (Journal or Book title)

International journal of cardiology

First Page

186

Last Page

189

Recommended Citation

Grewal, U. S., Thotamgari, S. R., Sheth, A. R., Gaddam, S. J., Ahmad, J., Beedupalli, K., & Dominic, P. (2021). Cardiovascular complications associated with novel agents in the chronic lymphocytic leukemia armamentarium: A pharmacovigilance analysis. International journal of cardiology, 344, 186-189. https://doi.org/10.1016/j.ijcard.2021.10.011

This document is currently not available here.

COinS